BidaskClub upgraded shares of Tabula Rasa HealthCare (NASDAQ:TRHC) from a hold rating to a buy rating in a report released on Tuesday.

Several other research analysts also recently commented on TRHC. Piper Jaffray Companies raised their price objective on shares of Tabula Rasa HealthCare to $71.00 and gave the stock an overweight rating in a report on Wednesday, August 8th. Zacks Investment Research raised shares of Tabula Rasa HealthCare from a hold rating to a buy rating and set a $74.00 price objective for the company in a report on Saturday, August 11th. Citigroup raised their price objective on shares of Tabula Rasa HealthCare from $57.00 to $76.00 and gave the stock a buy rating in a report on Thursday, August 9th. Stifel Nicolaus assumed coverage on shares of Tabula Rasa HealthCare in a report on Tuesday, September 11th. They issued a hold rating and a $95.00 price objective for the company. Finally, Robert W. Baird reaffirmed a buy rating and issued a $70.00 price objective on shares of Tabula Rasa HealthCare in a report on Wednesday, August 8th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Tabula Rasa HealthCare has a consensus rating of Buy and a consensus price target of $81.60.

TRHC opened at $72.96 on Tuesday. The company has a market capitalization of $1.36 billion, a P/E ratio of -1,824.00, a price-to-earnings-growth ratio of 5.08 and a beta of 2.58. Tabula Rasa HealthCare has a 12 month low of $27.10 and a 12 month high of $91.16. The company has a quick ratio of 0.33, a current ratio of 0.36 and a debt-to-equity ratio of 0.11.

Tabula Rasa HealthCare (NASDAQ:TRHC) last released its quarterly earnings data on Tuesday, November 6th. The company reported $0.26 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.07. The company had revenue of $54.42 million during the quarter, compared to the consensus estimate of $52.87 million. Tabula Rasa HealthCare had a negative net margin of 13.49% and a positive return on equity of 7.53%. Tabula Rasa HealthCare’s revenue for the quarter was up 66.3% on a year-over-year basis. During the same period last year, the firm earned $0.08 EPS. On average, equities analysts expect that Tabula Rasa HealthCare will post 0.53 earnings per share for the current year.

In other Tabula Rasa HealthCare news, President Orsula V. Knowlton sold 8,000 shares of the firm’s stock in a transaction on Friday, August 17th. The shares were sold at an average price of $72.23, for a total value of $577,840.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders sold 48,000 shares of company stock valued at $3,722,960. Insiders own 14.00% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. boosted its holdings in Tabula Rasa HealthCare by 20.8% in the 3rd quarter. BlackRock Inc. now owns 2,560,710 shares of the company’s stock valued at $207,904,000 after purchasing an additional 441,203 shares during the period. Jennison Associates LLC boosted its holdings in Tabula Rasa HealthCare by 29.5% in the 2nd quarter. Jennison Associates LLC now owns 757,846 shares of the company’s stock valued at $48,373,000 after purchasing an additional 172,693 shares during the period. NN Investment Partners Holdings N.V. boosted its holdings in Tabula Rasa HealthCare by 45.2% in the 3rd quarter. NN Investment Partners Holdings N.V. now owns 669,800 shares of the company’s stock valued at $54,380,000 after purchasing an additional 208,604 shares during the period. Braun Stacey Associates Inc. boosted its holdings in Tabula Rasa HealthCare by 199.0% in the 2nd quarter. Braun Stacey Associates Inc. now owns 301,089 shares of the company’s stock valued at $19,219,000 after purchasing an additional 200,394 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Tabula Rasa HealthCare by 20.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 258,613 shares of the company’s stock valued at $20,996,000 after purchasing an additional 44,551 shares during the period. 75.88% of the stock is owned by hedge funds and other institutional investors.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

See Also: Find a Trading Strategy That Works

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.